DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA393392
Title:
Radiation-Induced Chemosensitization Potentiation of Antitumor Activity of Polymer-Drug Conjugates
Descriptive Note:
Annual rept. 1 Apr 2000-31 Mar 2001
Corporate Author:
M D ANDERSON CANCER CENTER HOUSTON TX
Report Date:
2001-04-01
Pagination or Media Count:
28.0
Abstract:
Although combined chemotherapy and radiotherapy has produced significantly improved response and survival rates among cancer patients, there is still a compelling need to establish the most effective way to deliver these agents. The ultimate goal of this study is to develop a more effective treatment regimen for preventing both systemic relapse and local-regional recurrence in breast cancer patients. We hypothesize that radiation enhances the antitumor activity of polymer-drug conjugates by increasing tumor vascular permeability and thus enhancing the tumor uptake of PG-TXL. Using a water-soluble polyL-glutamic acid-conjugated paclitaxel PG-TXL as a model compound, we demonstrated that combined radiation and PG-TXL produced a significantly greater tumor growth delay than treatment with combined radiation and paclitaxel. Furthermore, supperadditive interaction with enhancement factors ranging from 2.0 to 4.3 was also observed when PG-TXL was given 4-72 hr before tumor irradiation, suggesting that PG-TXL may in turn sensitize tumor response toward radiation. Our data support a treatment strategy combining radiation and polymeric chemotherapy that may have important clinical implications in terms of scheduling and optimization of the therapeutic ratio.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
